Clinical trial
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol…
NCT00152386 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00152386 |
|---|---|
| Title | A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis |
| Official title | A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Certolizumab pegol (CDP870) |
| Enrollment | 950 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 9, 2005 |
| Last update posted | Dec 1, 2020 |
| Countries | Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Israel, Latvia, Russia, Ukraine and 1 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: